Professor Peter Smith joins LITFL and CALIBER Magazine as contributing author

By AI, Created 4:46 PM UTC, May 18, 2026, /AGP/ – Professor Peter Smith, one of Australia’s most published clinical immunologists, has joined Life in the Fast Lane and CALIBER Magazine as a contributing author. His columns will focus on longevity medicine, chronic disease immunology and the science of healthspan, with the first LITFL pieces already underway.

Why it matters: - Peter Smith’s move puts a high-profile immunologist in front of two different audiences: clinicians at Life in the Fast Lane and high-performing professionals at CALIBER Magazine. - The assignment signals growing mainstream interest in longevity medicine, healthspan and the biology behind chronic disease. - Smith’s background in allergy, immunology and post-viral illness research gives the columns medical weight, not just lifestyle framing.

What happened: - Professor Peter Kenneth Smith has joined Life in the Fast Lane and CALIBER Magazine as a contributing author. - The announcement was made May 13, 2026, from Southport, Queensland, Australia. - Smith will write about the science of living longer and better, including longevity medicine, chronic disease immunology and overlooked drivers of health. - His contributions to LITFL began in April 2026.

The details: - Smith is a former consultant in Pediatric Allergy at Great Ormond Street Hospital in London. - He holds Emeritus Professorial status at Griffith University and serves as Clinical Lead at the Menzies National Centre for Neuroimmunology. - He is also Professor in Allergy at OPRI Singapore. - Smith has authored more than 170 peer-reviewed papers, supervised more than 60 higher-degree students across three countries and contributed to five medical textbooks. - His books include the Royal Society of Medicine Book Award-winning Great Ormond Street Colour Handbook of Paediatric Medicine and Surgery. - Smith’s research group was the first to identify TRPM3 ion channel dysfunction as a mechanism in myalgic encephalomyelitis and long COVID. - The group also showed that low-dose naltrexone can restore TRPM3 function in natural killer cells from affected patients. - LITFL is a free open-access medical education platform with more than 259 million visitors to date. - CALIBER Magazine covers ideas, performance and lifestyle for founders, executives and professionals. - Smith’s CALIBER columns will sit at the intersection of medicine, performance and decision-making. - He is co-Chair of EUFOREA’s Rhinitis division, sits on the Expert International Scientific Advisory Board of the Allergy Centre of Excellence in London and is a faculty member of the Global Anaphylaxis and Food Allergy initiative. - Smith is co-founder of Natural Pearl Skincare and a director of Pearl Consumer Health Pte. Ltd. in Singapore. - He also holds a PhD in molecular immunology from Flinders University. - His appointments have included roles in Australia, the United Kingdom and Singapore, including Visiting Professor positions at University College London and Great Ormond Street Hospital. - Smith’s social profiles were listed at LinkedIn and ResearchGate.

Between the lines: - LITFL gives Smith a direct line to clinicians who may apply longevity and recovery ideas in practice. - CALIBER gives the same topics a more commercial and executive audience, where healthspan is increasingly framed as a productivity and decision-making issue. - The release positions post-viral illness research as part of the broader longevity conversation, not a niche topic.

What’s next: - Smith’s LITFL series is expected to continue with practical coverage of longevity supplementation, sleep, recovery and physician healthspan. - CALIBER columns will expand his reach into the founder and executive audience. - The partnership may further elevate discussions around immunology, chronic disease and health optimization across both publications.

The bottom line: - Peter Smith is turning a deep immunology background into public-facing commentary on longevity, with two platforms aimed at very different but influential audiences.